Lennar (LEN) Gets a Hold from Evercore ISI
Evercore ISI analyst Stephen Kim maintained a Hold rating on Lennar (LEN – Research Report) yesterday and set a price target of $131.00. The company's shares closed yesterday at $104.61.
Confident Investing Starts Here:
According to TipRanks, Kim is a 5-star analyst with an average return of 14.2% and a 57.84% success rate. Kim covers the Consumer Cyclical sector, focusing on stocks such as Lennar, Installed Building Products, and KB Home.
In addition to Evercore ISI, Lennar also received a Hold from KBW's Jade Rahmani in a report issued yesterday. However, on the same day, UBS reiterated a Buy rating on Lennar (NYSE: LEN).
Based on Lennar's latest earnings release for the quarter ending February 28, the company reported a quarterly revenue of $7.63 billion and a net profit of $519.53 million. In comparison, last year the company earned a revenue of $7.31 billion and had a net profit of $719.33 million
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Retail Traders Just Sent This AI Health Stock Soaring 60%
Oscar Health (NYSE:OSCR) has exploded nearly 60% this week, adding close to $2 billion in market cap without a single press release or earnings update. The real catalyst? A retail trading frenzy. OSCR became one of the most-mentioned names on r/WallStreetBets, and trading volume followed suitnearly 50 million shares changed hands on Wednesday alone, the second-highest in the company's history. Options activity lit up as well, with call volumes hitting a record 152,414 that day, and another 95,000 contracts moving by Friday morning, nearly triple the norm. Beneath the surge is a company with serious revenue momentumup 48% in 2023 and 57% in 2024. Adjusted earnings per share reached $0.92 in Q1 2025. But Oscar isn't just selling insuranceit's selling a story. Management brands the company as a health-tech platform, powered by AI and run on what it calls a continuous hackathon model. That pitch, familiar to anyone who's followed high-multiple tech names, is likely helping Oscar catch a more generous valuation than traditional insurers. Retail traders appear to be buying into that promise. Another factor? The Kushner connection. Joshua Kushner, vice chairman of Oscar's board and brother to Jared Kushner, has remained a prominent name in business and politics alike. That visibility might be adding an extra layer of speculation to the mix. But for now, the stock's movement is being driven more by momentum than fundamentals. Oscar is just $3 shy of its all-time highand the retail crowd seems determined to carry it the rest of the way. This article first appeared on GuruFocus.
Yahoo
an hour ago
- Yahoo
Evercore ISI Keeps Outperform Rating on ExxonMobil (XOM)
Exxon Mobil Corporation (NYSE:XOM) is one of the 10 Best Oil and Gas Stocks to Buy Now. On June 3, Evercore ISI analysts maintained an 'Outperform' rating with a price target of $120 on Exxon Mobil Corporation (NYSE:XOM). This decision comes after a lunch meeting in New York City with the company's CEO, Darran Woods, where Exxon's strategic advantages over its peers were discussed. Aerial view of a major oil rig in the middle of the sea, pumping crude oil. The analysts noted that Exxon Mobil Corporation (NYSE:XOM) has better chances for higher returns in its upstream business and has an efficient downstream scale. The company's streamlined corporate cost structure and operating model were highlighted as key reasons that position the company well for better returns on capital. Exxon Mobil Corporation's (NYSE:XOM) efforts to reduce the effects of changing oil prices were highlighted. Over the past 9 years, especially under Wood's leadership, the company has focused on cutting costs, successfully completed big projects, and investments based on a $35 per barrel assumption. These actions are expected to help Exxon Mobil Corporation (NYSE:XOM) perform better than its competitors. Analysts also highlighted the company's ability to manage hydrogen and carbon, which are used in all parts of the business, including low-carbon initiatives. This approach is seen as unique and coherent, making Exxon Mobil Corporation's (NYSE:XOM) value proposition and business outlook more stable. To conclude, the report states that XOM will continue to attract a larger share of energy investment flows, from both active and passive investors, and Exxon Mobil Corporation (NYSE:XOM) will remain a leader in the energy industry. Exxon Mobil Corporation (NYSE:XOM) is an American oil and gas company that manages an industry-leading portfolio of resources. It is one of the world's largest integrated fuels, lubricants, and chemical companies. While we acknowledge the potential of XOM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Stocks That Will Bounce Back According To Analysts and 11 Best Stocks Under $15 to Buy According to Hedge Funds. Disclosure: None. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements
NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ('AIM' or the 'Company') (NYSE American: AIM) today announced the receipt of a warning notification (the 'Letter') from the NYSE American LLC (the 'NYSE American') stating that the Company is not in compliance with the minimum stockholders' equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the 'Company Guide') requiring stockholders' equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of March 31, 2025, the Company had a stockholders' deficit of negative $3.9 million and has had losses in the most recent five fiscal years ended December 31, 2024. The NYSE American previously issued a warning on December 17, 2024 for the same reasons and has issued the Letter because the deficiency remains as of March 31, 2025, when the Company filed its quarterly report on Form 10-Q for the first quarter of fiscal 2025. On February 26, 2025, the NYSE American accepted a plan submitted by the Company to regain compliance by June 11, 2026. Accordingly, the Company still has until June 11, 2026 to regain compliance. The Company's common stock recommenced trading on the NYSE American on June 17, 2025 under the symbol 'AIM'. The Letter in no way has any effect on such trading and does not affect the Company's business, operations or reporting requirements with the U.S. Securities and Exchange Commission. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company's intention to regain compliance with the listing requirements of the NYSE American and its ability to do so. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained herein speak only as of the date hereof, and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, subsequent events or otherwise, except as required by law. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@ in to access your portfolio
